Using TEE to Evaluate the Effect of Levosimendan on Patients With ARDS Associated With RVD During MV
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
Acute respiratory distress syndrome (ARDS) is often complicated by right ventricular
dysfunction (RVD), Acute cor pulmonale is the most serious form of ARDS complicated with
RVD.Levosimendan is indicated for short-term treatment of acute decompensated heart failure
that is not responding well to conventional therapy and requires increased myocardial
contractile force.In 2016, the European Society of Cardiology issued recommendations for the
management of acute right heart failure, stating that levosimendan can improve right
ventriculo-pulmonary artery coupling by both increasing right heart contractility and
reducing pulmonary vascular resistance.However, the clinical application of levosimendan in
the treatment of ARDS right heart dysfunction is insufficient.Therefore, this study intends
to use transesophageal ultrasound to evaluate right ventricular function, reduce the
limitation of poor right ventricular window in transthoracic echocardiography, and conduct a
multi-center randomized controlled study to further explore the effects of levosimendan on
right ventricular function in ARDS patients, such as tricuspid ring systolic displacement
(TAPSE) and tricuspid ring systolic displacement velocity (S '). Effects of right ventricular
area change fraction (RV FAC), right ventricular end-diastolic area/left ventricular
end-diastolic area (RVEDA/LVEDA), pulmonary circulation resistance (PVR), hemodynamics and
mortality.